STK39, overexpressed in osteosarcoma, regulates osteosarcoma cell invasion and proliferation

Huang,Tao; Zhou,Yuan; Cao,Yun; Tao,Jie; Zhou,Zhi-Hui; Hang,Dong-Hua

doi:10.3892/ol.2017.6728

STK39, overexpressed in osteosarcoma, regulates osteosarcoma cell invasion and proliferation

Authors:
- Tao Huang
- Yuan Zhou
- Yun Cao
- Jie Tao
- Zhi-Hui Zhou
- Dong-Hua Hang
View Affiliations

Affiliations: Department of Orthopedics, Baoshan Branch of Shanghai First People's Hospital, Shanghai 200940, P.R. China, Department of Orthopedics, Shanghai First People's Hospital, Shanghai 200080, P.R. China
Published online on: August 7, 2017 https://doi.org/10.3892/ol.2017.6728
Pages: 4599-4604
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Serine/threonine kinase 39 (STK39) is associated with hypertension, autism, Parkinson's disease and various types of cancer in recent years. This study investigated STK39 expression and possible roles in osteosarcoma using qPCR and western blot analysis. Compared to normal bone tissues, the mRNA and protein expression of STK39 was found to be upregulated in osteosarcoma. Using small interfering RNA transfection, STK39 was knocked down into two cell lines of osteosarcoma, U2OS and MG63, and the effects exerted on cell functioning were examined. The results showed that STK39 downregulation inhibited ostesarcoma cell proliferation and invasion. Moreover, STK39 knockdown in osteosarcoma cells significantly affected the expression of proteins connected to cell proliferation (proliferating cell nuclear antigen and p21) and invasion [Twist1, matrix metalloproteinase (MMP)2 and MMP9]. Phosphorylation of Smad2/3 was reduced by STK39 knock down. In conclusion, our data provide evidence that STK39 was overexpressed in osteosarcoma. STK39 may serve as an oncogene by adjusting the proliferation and invasion of osteosarcoma cells.

View Figures

View References

1	Gill J, Ahluwalia MK, Geller D and Gorlick R: New targets and approaches in osteosarcoma. Pharmacol Ther. 137:89–99. 2013. View Article : Google Scholar : PubMed/NCBI
2	Tan ML, Choong PF and Dass CR: Osteosarcoma: Conventional treatment vs gene therapy. Cancer Biol Ther. 8:106–117. 2009. View Article : Google Scholar : PubMed/NCBI
3	Bakhshi S and Radhakrishnan V: Prognostic markers in osteosarcoma. Expert Rev Anticancer Ther. 10:271–287. 2010. View Article : Google Scholar : PubMed/NCBI
4	Guise TA, O'Keefe R, Randall RL and Terek RM: Molecular biology and therapeutics in musculoskeletal oncology. J Bone Joint Surg Am. 91:724–732. 2009. View Article : Google Scholar : PubMed/NCBI
5	Ramoz N, Cai G, Reichert JG, Silverman JM and Buxbaum JD: An analysis of candidate autism loci on chromosome 2q24-q33: evidence for association to the STK39 gene. Am J Med Genet B Neuropsychiatr Genet. 147B:1152–1158. 2008. View Article : Google Scholar : PubMed/NCBI
6	Johnston AM, Naselli G, Gonez LJ, Martin RM, Harrison LC and DeAizpurua HJ: SPAK, a STE20/SPS1-related kinase that activates the p38 pathway. Oncogene. 19:4290–4297. 2000. View Article : Google Scholar : PubMed/NCBI
7	Chen LY, Zhao WH, Tian W, Guo J, Jiang F, Jin LJ, Sun YX, Chen KM, An LL, Li GD, et al: STK39 is an independent risk factor for male hypertension in Han Chinese. Int J Cardiol. 154:122–127. 2012. View Article : Google Scholar : PubMed/NCBI
8	Wang Y, O'Connell JR, McArdle PF, Wade JB, Dorff SE, Shah SJ, Shi X, Pan L, Rampersaud E, Shen H, et al: From the Cover: Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci USA. 106:226–231. 2009. View Article : Google Scholar : PubMed/NCBI
9	Ramoz N, Cai G, Reichert JG, Silverman JM and Buxbaum JD: An analysis of candidate autism loci on chromosome 2q24-q33: Evidence for association to the STK39 gene. Am J Med Genet B Neuropsychiatr Genet. 147B:1152–1158. 2008. View Article : Google Scholar : PubMed/NCBI
10	Li NN, Tan EK, Chang XL, Mao XY, Zhang JH, Zhao DM, Liao Q, Yu WJ and Peng R: Genetic association study between STK39 and CCDC62/HIP1R and Parkinson's disease. PLoS One. 8:e792112013. View Article : Google Scholar : PubMed/NCBI
11	Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J and Jenster G: Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res. 66:5012–5020. 2006. View Article : Google Scholar : PubMed/NCBI
12	Balatoni CE, Dawson DW, Suh J, Sherman MH, Sanders G, Hong JS, Frank MJ, Malone CS, Said JW and Teitell MA: Epigenetic silencing of Stk39 in B-cell lymphoma inhibits apoptosis from genotoxic stress. Am J Pathol. 175:1653–1661. 2009. View Article : Google Scholar : PubMed/NCBI
13	Li Z, Zhu W, Xiong L, Yu X, Chen X and Lin Q: Role of high expression levels of STK39 in the growth, migration and invasion of non-small cell type lung cancer cells. Oncotarget. 7:61366–61377. 2016. View Article : Google Scholar : PubMed/NCBI
14	Kubben FJ, Peeters-Haesevoets A, Engels LG, Baeten CG, Schutte B, Arends JW, Stockbrügger RW and Blijham GH: Proliferating cell nuclear antigen (PCNA): A new marker to study human colonic cell proliferation. Gut. 35:530–535. 1994. View Article : Google Scholar : PubMed/NCBI
15	Gartel AL and Radhakrishnan SK: Lost in transcription: p21 repression, mechanisms and consequences. Cancer Res. 65:3980–3985. 2005. View Article : Google Scholar : PubMed/NCBI
16	Yang G, Yuan J and Li K: EMT transcription factors: Implication in osteosarcoma. Med Oncol. 30:6972013. View Article : Google Scholar : PubMed/NCBI
17	Matsuyama S, Iwadate M, Kondo M, Saitoh M, Hanyu A, Shimizu K, Aburatani H, Mishima HK, Imamura T, Miyazono K, et al: SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res. 63:7791–7798. 2003.PubMed/NCBI
18	Li F, Li S and Cheng T: TGF-β1 promotes osteosarcoma cell migration and invasion through the miR-143-versican pathway. Cell Physiol Biochem. 34:2169–2179. 2014. View Article : Google Scholar : PubMed/NCBI
19	Waga S, Hannon GJ, Beach D and Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 369:574–578. 1994. View Article : Google Scholar : PubMed/NCBI
20	Wang W, Luo H and Wang A: Expression of survivin and correlation with PCNA in osteosarcoma. J Surg Oncol. 93:578–584. 2006. View Article : Google Scholar : PubMed/NCBI
21	Cottam D and Rees R: Regulation of matrix metalloproteinases - their role in tumor invasion and metastasis (Review). Int J Oncol. 2:861–872. 1993.PubMed/NCBI
22	Yin K, Liao Q, He H and Zhong D: Prognostic value of Twist and E-cadherin in patients with osteosarcoma. Med Oncol. 29:3449–3455. 2012. View Article : Google Scholar : PubMed/NCBI
23	Massagué J: TGF-β signaling in development and disease. FEBS Lett. 586:1833. 2012. View Article : Google Scholar : PubMed/NCBI